ÂÜÀòÂÒÂ×

Dr. Jarvis is Chief Scientific Officer at Keystone Symposia. She brings 20+ years of experience in biopharmaceutical drug discovery and development and is a co-author of 40 publications and over a dozen patents. Dr. Jarvis serves as Principal Investigator on several grants supporting preclinical drug discovery at Crestone, and as scientific liaison with NIAID for Phase I clinical studies of CRS3123 for treatment of Clostridium difficile infections.

From 2009 to 2012, Dr. Jarvis worked at SomaLogic as Director of Technology Development (part-time), and led a structural biology program to characterize modified DNA aptamers with diverse therapeutic and diagnostic applications. Before joining SomaLogic, Dr. Jarvis was Senior Director of Biochemistry at Replidyne (2002-2008), where she played an integral role in multiple antibacterial drug discovery projects and contributed to both IND and NDA regulatory filings. Her group was responsible for high throughput target-based screening for antibacterial drug leads, and structural and mechanistic characterization of enzyme inhibitors.

In early 2000, Dr. Jarvis co-founded Impact Biosciences, where she served as VP of R&D, focusing on target validation in mammalian cell culture systems. Prior to Impact, she served as Associate Director of Biology at Ribozyme Pharmaceuticals, Inc. (RPI) and its spin-off, Atugen USA. At RPI, Dr. Jarvis led discovery efforts for oligonucleotide-based therapeutics in the areas of oncology, arthritis, cardiovascular disease, and virology, resulting in two programs that progressed into clinical development. She also served as project leader and scientific liaison for several projects with corporate partners.

At Atugen, she pioneered the development of Atugen’s GeneBlocTM technology for the specific regulation of gene expression and implemented high throughput screening strategies for validating oncology targets in a variety of human tumor cell lines.

As a research scientist at Synergen (1992-1993), Dr. Jarvis worked on engineering protein-based therapeutics for inflammatory diseases. Dr. Jarvis currently serves as an advisor to the Seattle Structural Genomics Center for Infectious Disease. Dr. Jarvis received her BA degree with distinction in Chemistry from Carleton College in Northfield, MN. She received her Ph.D. in Chemistry from the University of Oregon, where her doctoral work focused on the mechanisms of bacteriophage DNA replication.